These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 20533437)

  • 1. A technical feasibility study of dornase alfa delivery with eFlow® vibrating membrane nebulizers: aerosol characteristics and physicochemical stability.
    Scherer T; Geller DE; Owyang L; Tservistas M; Keller M; Boden N; Kesser KC; Shire SJ
    J Pharm Sci; 2011 Jan; 100(1):98-109. PubMed ID: 20533437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of efficacy and safety of dornase alfa delivered by eRapid nebulizer in cystic fibrosis patients.
    Sawicki GS; Chou W; Raimundo K; Trzaskoma B; Konstan MW
    J Cyst Fibros; 2015 Nov; 14(6):777-83. PubMed ID: 25921451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Dornase Alfa Nebulizer Group.
    Geller DE; Eigen H; Fiel SB; Clark A; Lamarre AP; Johnson CA; Konstan MW
    Pediatr Pulmonol; 1998 Feb; 25(2):83-7. PubMed ID: 9516090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sinonasal inhalation of dornase alfa administered by vibrating aerosol to cystic fibrosis patients: a double-blind placebo-controlled cross-over trial.
    Mainz JG; Schien C; Schiller I; Schädlich K; Koitschev A; Koitschev C; Riethmüller J; Graepler-Mainka U; Wiedemann B; Beck JF
    J Cyst Fibros; 2014 Jul; 13(4):461-70. PubMed ID: 24594542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physicochemical compatibility and stability of nebulizable drug admixtures containing Dornase alfa and tobramycin.
    Klemmer A; Krämer I; Kamin W
    Pulm Pharmacol Ther; 2014 Jun; 28(1):53-59. PubMed ID: 24035821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aerosol Delivery of Dornase Alfa Generated by Jet and Mesh Nebulizers.
    Chang KH; Moon SH; Yoo SK; Park BJ; Nam KC
    Pharmaceutics; 2020 Jul; 12(8):. PubMed ID: 32751886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physicochemical compatibility of mixtures of dornase alfa and tobramycin containing nebulizer solutions.
    Krämer I; Schwabe A; Lichtinghagen R; Kamin W
    Pediatr Pulmonol; 2009 Feb; 44(2):134-41. PubMed ID: 19061233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change.
    VanDevanter DR; Craib ML; Pasta DJ; Millar SJ; Morgan WJ; Konstan MW;
    Pediatr Pulmonol; 2018 Jan; 53(1):43-49. PubMed ID: 29064184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dornase alfa. A review of its pharmacological properties and therapeutic potential in cystic fibrosis.
    Bryson HM; Sorkin EM
    Drugs; 1994 Dec; 48(6):894-906. PubMed ID: 7533697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities.
    Quan JM; Tiddens HA; Sy JP; McKenzie SG; Montgomery MD; Robinson PJ; Wohl ME; Konstan MW;
    J Pediatr; 2001 Dec; 139(6):813-20. PubMed ID: 11743506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vibrating membrane devices deliver aerosols more efficient than standard devices: a study in a neonatal upper airway model.
    Tiemersma S; Minocchieri S; van Lingen RA; Nelle M; Devadason SG
    J Aerosol Med Pulm Drug Deliv; 2013 Oct; 26(5):280-6. PubMed ID: 23273244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.
    Hodson ME
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S70-4. PubMed ID: 7881698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small airway deposition of dornase alfa during exacerbations in cystic fibrosis; a randomized controlled clinical trial.
    Bakker EM; Volpi S; Salonini E; Müllinger B; Kroneberg P; Bakker M; Hop WC; Assael BM; Tiddens HA
    Pediatr Pulmonol; 2014 Feb; 49(2):154-61. PubMed ID: 23913868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physicochemical aspects and efficiency of albuterol nebulization: comparison of three aerosol types in an in vitro pediatric model.
    Sidler-Moix AL; Di Paolo ER; Dolci U; Berger-Gryllaki M; Cotting J; Pannatier A
    Respir Care; 2015 Jan; 60(1):38-46. PubMed ID: 25516995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebuliser systems for drug delivery in cystic fibrosis.
    Daniels T; Mills N; Whitaker P
    Cochrane Database Syst Rev; 2013 Apr; (4):CD007639. PubMed ID: 23633344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aerosolized dornase alfa in cystic fibrosis: is there a role in the management of patients with early obstructive lung disease?
    Geller DE
    Pediatr Pulmonol; 1997 Aug; 24(2):155-8; discussion 159-61. PubMed ID: 9292913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: A technical feasibility study.
    Mahri S; Wilms T; Hagedorm P; Guichard MJ; Vanvarenberg K; Dumoulin M; Frijlink H; Vanbever R
    Eur J Pharm Sci; 2023 Oct; 189():106522. PubMed ID: 37423579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A crossover, randomized, controlled trial of dornase alfa before versus after physiotherapy in cystic fibrosis.
    Fitzgerald DA; Hilton J; Jepson B; Smith L
    Pediatrics; 2005 Oct; 116(4):e549-54. PubMed ID: 16147970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is a longer time interval between recombinant human deoxyribonuclease (dornase alfa) and chest physiotherapy better? A multi-center, randomized crossover trial.
    Wilson CJ; Robbins LJ; Murphy JM; Chang AB
    Pediatr Pulmonol; 2007 Dec; 42(12):1110-6. PubMed ID: 17955550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients.
    Rottier BL; van Erp CJ; Sluyter TS; Heijerman HG; Frijlink HW; Boer AH
    J Aerosol Med Pulm Drug Deliv; 2009 Sep; 22(3):263-9. PubMed ID: 19466906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.